Ensign Peak Advisors Inc Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

Ensign Peak Advisors Inc raised its position in Eli Lilly and Company (NYSE:LLY) by 0.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 879,138 shares of the company’s stock after acquiring an additional 2,726 shares during the quarter. Eli Lilly and Company makes up 1.2% of Ensign Peak Advisors Inc’s investment portfolio, making the stock its 13th largest position. Ensign Peak Advisors Inc owned 0.09% of Eli Lilly and Company worth $678,695,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of LLY. Ethic Inc. raised its position in Eli Lilly and Company by 9.1% during the 4th quarter. Ethic Inc. now owns 76,146 shares of the company’s stock valued at $58,784,000 after purchasing an additional 6,379 shares during the last quarter. Fiduciary Trust Co raised its holdings in shares of Eli Lilly and Company by 9.1% during the fourth quarter. Fiduciary Trust Co now owns 9,340 shares of the company’s stock valued at $7,211,000 after acquiring an additional 779 shares in the last quarter. Fullcircle Wealth LLC purchased a new stake in Eli Lilly and Company in the fourth quarter worth $895,000. Coastal Bridge Advisors LLC boosted its holdings in Eli Lilly and Company by 21.3% in the fourth quarter. Coastal Bridge Advisors LLC now owns 660 shares of the company’s stock valued at $510,000 after acquiring an additional 116 shares in the last quarter. Finally, Duquesne Family Office LLC purchased a new position in Eli Lilly and Company during the 4th quarter valued at $48,011,000. 82.53% of the stock is owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Down 3.2 %

Eli Lilly and Company stock opened at $752.02 on Friday. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The business’s fifty day moving average is $814.48 and its 200 day moving average is $812.71. The stock has a market capitalization of $712.72 billion, a PE ratio of 64.22, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the prior year, the firm earned $2.58 earnings per share. The business’s revenue was up 45.2% compared to the same quarter last year. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.80%. Eli Lilly and Company’s payout ratio is 48.82%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on LLY shares. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their target price for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. HSBC lowered Eli Lilly and Company from a “buy” rating to a “reduce” rating and dropped their price target for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Finally, UBS Group decreased their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,002.80.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.